AVTX Avalo Therapeutics Inc

Price (delayed)

$13.58

Market cap

$713.84M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.46

Enterprise value

$688.71M

?
Relative Growth: Rel. Growth: 2
Relative Strength: Rel. Strength: 79
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 19

Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of ...

Highlights
The EPS has contracted by 36% YoY but it has grown by 7% from the previous quarter
The company's gross profit has shrunk by 92% YoY
AVTX's revenue has shrunk by 87% YoY

Key stats

What are the main financial stats of AVTX

AVTX stock price

How has the Avalo Therapeutics stock price performed over time
Intraday
-1.16%
1 week
-15.81%
1 month
-1.45%
1 year
212.18%
YTD
-25.22%
QTD
-9.04%

Financial performance

How have Avalo Therapeutics's revenue and profit performed over time
Revenue
$59,000
Gross profit
$59,000
Operating income
-$79.16M
Net income
-$84.74M
Gross margin
100%
Net margin
-143,627.1%
The company's gross profit has shrunk by 92% YoY
AVTX's revenue has shrunk by 87% YoY
AVTX's operating income has shrunk by 57% YoY and by 9% QoQ
Avalo Therapeutics's gross margin has decreased by 39% YoY

Price vs fundamentals

How does AVTX's price correlate with its fundamentals

Growth

What is Avalo Therapeutics's growth rate over time

Valuation

What is Avalo Therapeutics stock price valuation
P/E
N/A
P/B
4.53
P/S
4,628
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11,672.97
The EPS has contracted by 36% YoY but it has grown by 7% from the previous quarter
AVTX's P/B is 64% above its last 4 quarters average of 2.8
The equity has contracted by 44% YoY and by 18% from the previous quarter
AVTX's revenue has shrunk by 87% YoY
The P/S is 82% higher than the last 4 quarters average of 2565.8

Efficiency

How efficient is Avalo Therapeutics business performance
The ROE has dropped by 188% year-on-year and by 25% since the previous quarter
Avalo Therapeutics's ROA has decreased by 17% from the previous quarter
The return on invested capital rose by 14% since the previous quarter
The ROS has contracted by 8% from the previous quarter

Dividends

What is AVTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AVTX.

Financial health

How did Avalo Therapeutics financials performed over time
AVTX's total liabilities has surged by 98% year-on-year but it is down by 6% since the previous quarter
Avalo Therapeutics's quick ratio has plunged by 68% YoY and by 7% from the previous quarter
The debt is 100% smaller than the equity
The equity has contracted by 44% YoY and by 18% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.